Suppr超能文献

美罗培南在接受持续血液透析滤过治疗的急性肾衰竭重症患者中的药代动力学。

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

作者信息

Krueger W A, Schroeder T H, Hutchison M, Hoffmann E, Dieterich H J, Heininger A, Erley C, Wehrle A, Unertl K

机构信息

Department of Anesthesiology, Tübingen University Hospital, Tübingen, Germany.

出版信息

Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4. doi: 10.1128/AAC.42.9.2421.

Abstract

The pharmacokinetics of meropenem were studied in nine anuric critically ill patients treated by continuous venovenous hemodiafiltration. Peak levels after infusion of 1,000 mg over 30 min amounted to 103.2 +/- 45.9 microgram/ml, and trough levels at 12 h were 9.6 +/- 3.8 microgram/ml. A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms. Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with lower clearances are applied.

摘要

对9例接受持续静脉-静脉血液透析滤过治疗的无尿重症患者进行了美罗培南的药代动力学研究。在30分钟内输注1000毫克后,峰值水平达到103.2±45.9微克/毫升,12小时的谷值水平为9.6±3.8微克/毫升。每天两次1000毫克的美罗培南剂量可提供覆盖中度敏感微生物的血浆药物水平。对于高度敏感细菌或应用清除率较低的肾脏替代疗法时,可能需要进一步降低剂量。

相似文献

引用本文的文献

本文引用的文献

5
Meropenem: a microbiological overview.美罗培南:微生物学概述。
J Antimicrob Chemother. 1995 Jul;36 Suppl A:1-17. doi: 10.1093/jac/36.suppl_a.1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验